Common use of Publications Clause in Contracts

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least *** days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** days from the date of delivery to the other Party. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, or other studies with respect to any the Licensed Compound in the Lead Indication Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within [*** *] days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** *] days from the date of delivery to the other Party. Failure to respond within such [***] days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional [*** *] days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Studies with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plancontracts, to agree to terms substantially similar to those set forth in this SectionSection 9.5, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 9.5 with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, Information and Inventions regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided that such publications are subject to reasonable controls to protect each Party’s Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studies, or Clinical Studies generated by the other studies with respect to any Licensed Compound in the Lead Indication Party or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing or presenting Party within [*** *] days of after the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** *] days from after the date of delivery to the other Party. If Failure to respond within such [***] days shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s written request to (a) delete references to such other Party’s Confidential Information in any such paper and will or presentation or (b) withhold publication of any such paper or any presentation of same for an additional [*** *] days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data from, or pertains to results of clinical studiesof, any Impax Study or other studies with respect to any Licensed Compound AstraZeneca Study in the Lead Indication Field, or that includes Confidential Information of the other Party. Any such approval shall not be unreasonably withheld, conditioned or delayed. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** days *] prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within [*** days *] of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** days *] from the date of delivery to the other Party. Failure to respond within such [***] shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC Senior Officers for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will shall withhold publication of any such paper or any presentation of same for an additional [*** days *] in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use Commercially Reasonable Efforts to cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plancovered by this Section 11.6, to agree to terms substantially similar to those set forth in this SectionSection 11.6, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 11.6 with respect to such investigators and institutions. Notwithstanding the foregoing, in the case of AstraZeneca with respect to AstraZeneca Studies outside the Territory, AstraZeneca shall be deemed to satisfy its obligations under this Section 11.6 if it uses Commercially Reasonable Efforts to comply with this Section 11.6.

Publications. Each Party recognizes that the publication of papers regarding results of, Information and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided that such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filedconfidential information. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studies, Clinical Studies or includes other studies with respect to any Licensed Compound in the Lead Indication Information generated under this Agreement or that otherwise includes Confidential Information confidential information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** sixty (60) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing or presenting Party within *** sixty (60) days of after the delivery of such paper to the such other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as reasonably practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** sixty (60) days from after the date of delivery to the such other Party. If Failure to respond within such sixty (60) days shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s written request to to: (a) delete references to such other Party’s Confidential Information confidential information in any such paper and will or presentation; or (b) withhold publication of any such paper or any presentation of same for an additional *** one hundred twenty (120) days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use its respective Reasonable Commercial Efforts to cause investigators and institutions participating in clinical studies for the Licensed Product with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this SectionSection 5.7, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 5.7 with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided that such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any the Licensed Compound in the Lead Indication Compounds or Licensed Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** days **] prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within [*** days **] of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** twenty-five (25) days from the date of delivery to the other Party. Failure to respond within such twenty-five (25) days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC Senior Officers or their delegates for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional [*** days **] in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutions.

Publications. Each Party acknowledges the other Party’s interest in publishing the results of its activities under the Validation Program in order to obtain recognition within the scientific community and to advance the state of scientific knowledge, and each Party will be permitted to make such publications in accordance with this Section 8.7. Each Party also recognizes that the mutual interest in obtaining valid patent protection and in protecting business interests and trade secrets. Consequently, except for disclosures otherwise permitted pursuant to ARTICLE 3 or this ARTICLE 8, either Party, its employees or consultants wishing to make a publication of papers regarding results of, and other information regarding, its activities under this Agreement, including oral presentations and abstracts, may be beneficial the Validation Program shall deliver to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent other Party a copy of the Parties proposed written publication or an outline of an oral disclosure at least [***] days prior to maintain the confidentiality of any Confidential Information included in any invention disclosures submission for publication or draft Patent application until such Patent application has been filedpresentation. Accordingly, each The reviewing Party shall have the right (a) to review and approve any paper proposed propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication by or presentation in order to protect patentable information. If the other reviewing Party requests a delay for patent reasons, the publishing Party shall delay submission or presentation for a period of [***] days to enable patent applications protecting each Party’s rights in such information. Upon expiration of such [***] days, including any oral the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party requests modifications to the publication or presentation for trade secret or abstractbusiness reasons, that contains clinical data the publishing Party shall edit such publication to prevent disclosure of trade secret or pertains proprietary business information prior to results submission of clinical studiesthe publication or presentation. Notwithstanding the foregoing, or other studies if a Party becomes a Commercial Rights Party with respect to any Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is madea Validation Program ADC, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least will not have the right to make any publication that relates to such Validation Program ADC without the prior written consent of the Commercial Rights Party. [*** days prior *] Portions of this exhibit have been redacted pursuant to *** Confidential material redacted and a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** days from the date of delivery to the other Party. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, or other studies with respect to any the Licensed Compound in the Lead Indication Compounds or Licensed Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least […*** *…] ([…***…]) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within […*** *…] ([…***…]) days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** days from the date of delivery to the other Party. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. ***Confidential Treatment Requested*** Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional […*** *…] ([…***…]) days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use Commercially Reasonable Efforts to cause investigators and institutions participating in Clinical Studies with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plancontracts, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ such Party’s obligations under this Section with respect to such investigators and institutions.

Publications. Each The Parties recognize the desirability of publishing and publicly disclosing the results of clinical trials of pharmaceutical products. Accordingly, subject to coordination through designated representatives of each Party, the publishing Party recognizes that shall be free to publicly disclose the publication results of papers regarding results of, and other information regarding, activities under clinical trials involving Compounds or Products conducted pursuant to this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect prior review by the non-publishing Party for issues of patentability and protection of its Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies a manner consistent with respect to any Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least *** days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments all Laws applicable to the publishing Party within *** days and best industry practices. In addition, if either Party (the “Publishing Party”) intends to publish articles in scientific or medical journals or to make presentations of the delivery results of clinical trials involving Compounds or Products conducted pursuant to this Agreement, such paper to the other Party. With respect to oral presentation materials and abstracts, Party shall provide the other Party (the “Non-publishing Party”) through the designated representatives of each Party at its earliest opportunity with any proposed abstracts, manuscripts or summaries of presentations that cover the results of Development of any Compound or Product. The Non-publishing Party shall make reasonable efforts to expedite review respond promptly through its designated representative, and in any event no later than [***] days after receipt of such materials and abstractsproposed publication or presentation, and shall return or such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** days from the date of delivery to the other Party. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, shorter period as may be appropriaterequired by the publication. Receptos The Publishing Party agrees to allow a reasonable period (not to exceed [***] days) to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of the Non-Publishing Party. In addition, the Publishing Party will give due regard to comments furnished by the Non-publishing Party and such comments shall cause investigators not be unreasonably rejected. The Publishing Party shall be responsible to assure that its Subsidiaries and institutions with which it contracts for licensees agree to equivalent undertakings in favor of the conduct of clinical studies with respect Non-publishing Party. All publications involving Compounds or Products pursuant to any Licensed Compound this Agreement shall be in accordance with any guidelines or strategies promulgated by the Development Plan, to agree to terms substantially similar to those set forth in this SectionJDC, which efforts shall satisfy Receptos’ obligations under this Section include appropriate acknowledgement consistent with respect standard scientific practice of any contributions of each Party to such investigators and institutionsthe results being publicly disclosed.

Publications. Each Party to this Agreement recognizes that the publication of papers regarding results of, of and other information regarding, regarding Development or Commercialization activities under this Agreementwith respect to Product, including oral presentations and abstracts, may be beneficial to both PartiesParties as well as to Onxeo’s licensees outside the Territory, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each a Party shall have the right to review and approve comment on any paper material proposed for disclosure or publication by the other Party, including any such as by oral presentation presentation, manuscript or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any Licensed Compound in the Lead Indication or that which includes Confidential Information of the other Party. Before any such paper material is submitted for publication or an oral presentation is madepublication, the publishing or presenting Party proposing publication shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** thirty (30) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper material to a publisher or making the presentationinitiating any other disclosure. The Such other Party shall review any such paper material and give its comments to the publishing Party proposing publication within *** thirty (30) days of the delivery of such paper material to the such other Partyparty. With respect to oral presentation materials and abstracts, the such other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party proposing publication with appropriate comments, if any, but in no event later than *** thirty (30) days from the date of delivery to the other non-publishing Party. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the The publishing or presenting Party shall comply with the other Party’s request to delete references to such the other Party’s Confidential Information in any such paper material and will withhold agrees to delay any submission for publication or other public disclosure for a period of any such paper or any presentation of same for up to an additional *** ninety (90) days for the purpose of preparing and filing appropriate patent applications. During the Onxeo review process under this Section 13.11, Onxeo may disclose to its licensees outside the Territory the content of the proposed publication in order to permit obtain comments from such licensees, provided that any licensees are under confidentiality agreement with Onxeo regarding the Parties to obtain Patent protection if either Party deems it necessaryProduct. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriateCONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutionsASTERISKS ([***]) DENOTE SUCH OMISSIONS. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMMITTED INFORMATION.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, ; provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, or other studies with respect to any the Licensed Compound in the Lead Indication Compounds or Licensed Products, or that includes Confidential Information of the other Party; provided that following the Option Effective Date, (a) [†] have the right to publish papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, [†], and (b) [†] have the right to review and approve any paper proposed for publication by AbbVie under this Agreement, including any oral presentation or abstract, [†]. Before any such paper or abstract is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper paper, abstract or materials for oral presentation to the other Party at least *** days [†] prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper paper, abstract or materials to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** days [†] of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** days [†] from the date of delivery to the other Party. Failure to respond within such [†] shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC JGC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such the other Party’s Confidential Information in any such paper paper, abstract or materials and will shall withhold publication of any such paper paper, abstract or materials or any presentation of same for an additional *** days [†] in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data or which pertains to results of any clinical studies, studies or other studies with respect to the Licensed Product or includes other data generated under this Agreement or any Licensed Compound in Development Agreement or the Lead Indication or that includes Confidential Information of the other such first Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** thirty (30) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** fifteen (15) days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** fifteen (15) days from the date of delivery to the other Party. If Failure to respond within such fifteen (15) days shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the The publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** sixty (60) days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in any clinical studies for the Licensed Product with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ such Party’s obligations under this Section with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, or other studies Development activities with respect to any Licensed Compound in the Lead Indication New Collaboration Compounds or Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation; provided that the Parties may agree to a shorter period in exigent circumstances. The other Party shall review any such paper and give its comments to the publishing Party within [*** *] days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** *] days from the date of delivery to the other Party. Failure to respond within such [***] days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC JRDI or applicable JDC, as applicable for resolution together with the reasons for withholding approval. Notwithstanding If the foregoingJDC or JRDI, as applicable, does not resolve such dispute within [***] days, the publishing or presenting Party shall be entitled to publish such paper or make such presentation; provided that the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional [*** *] days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Studies with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plancontracts, to agree to terms substantially similar to those set forth in this SectionSection 15.5, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 15.5 with respect to such investigators and institutions.. Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 152

Publications. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studies, Clinical Trials or other studies with respect to any the Licensed Compound in the Lead Indication Product or that includes other data generated under this Agreement or which includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** forty-five (45) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** thirty (30) days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** thirty (30) days from the date of delivery to the other Party. Failure to respond within such thirty (30) days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC Dispute in accordance with Section 14.7 for resolution together with the reasons for withholding approvalresolution. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will shall withhold publication of any such paper or any presentation of same for an additional *** sixty (60) days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Trials for the Licensed Product with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this SectionSection 10.7, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 10.7 with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, regarding activities under this Agreement, including oral presentations and abstracts, Agreement may be beneficial to both Parties, ; provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent patent application until such Patent application has been filed. Accordingly, each Party (a) except as set in the attached Exhibit G, which Exhibit G sets forth all draft papers pending publication as of the Effective Date, Licensee shall have the right to review and approve approve, and (b) POZEN shall have the right to review and comment on, any paper proposed for publication by the other Party, Party or any of its Affiliates (including any oral presentation or abstract, ) that contains clinical data or pertains to results of pre-approval clinical studies, Phase 4 Trials, Post-Approval Commitments or other clinical studies with respect to any the Licensed Compound in the Lead Indication Products or that includes Confidential Information of the other Partydata generated under this Agreement (each a “Publication”). Before Prior to disclosing any such paper is submitted for publication or an oral presentation is madePublication, the publishing or presenting Party (or its applicable Affiliate) shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** thirty (30) calendar days prior to *** Confidential material redacted and filed separately with disclosing the Commission. submitting the paper to a publisher or making the presentationPublication. The other Party shall review any such paper Publication and give its comments comments, if any, (and, in the case of Licensee as the reviewing Party, notify POZEN whether or not it is granting its approval) to the publishing Party within *** fifteen (15) calendar days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other reviewing Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** fifteen (15) calendar days from the date of delivery to the other reviewing Party. If Failure by the reviewing Party to respond within such fifteen (15) calendar days shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the The publishing or presenting Party (or its applicable Affiliate) shall consider the comments of the other Party in good faith and shall comply with the other Party’s request to delete references to such other Party’s Confidential Information (or the Licensed Know-How, in the case of either Party as the reviewing Party) in any such paper Publication and will shall withhold publication of any such paper or any presentation of same Publication for an additional *** sixty (60) calendar days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Notwithstanding the foregoing, POZEN shall not request that Licensee delete references in Publications to clinical data owned by POZEN and contained in the NDA for the Initial Products, which clinical data Licensee may freely publish. Any publication Publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use Commercially Reasonable Efforts to cause investigators and institutions participating in pre-approval clinical studies, Phase IV Clinical Studies, Post-Approval Commitments or other clinical studies for the Licensed Products with which it contracts for the conduct of (but excluding in each case any investigator-sponsored human clinical studies with respect to any Licensed Compound in accordance with the Development Plan, studies) to agree to terms substantially similar to those set forth in this SectionSection 12.8, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 12.8 with respect to such investigators and institutions.

Publications. Each Party party to this Agreement recognizes that the publication of papers regarding containing results of, of and other information regarding, activities under this Agreementregarding development of Development Candidates (except as provided hereinafter), including oral presentations and abstracts, may be beneficial to both Parties, parties provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties parties to maintain the confidentiality of any Confidential Information included in any invention disclosures United States or draft Patent foreign application until such Patent United States or foreign patent application has been filedpublished. Accordingly, each Party the other party shall have the right and obligation to review and approve any paper proposed for publication by the other Partyparty, including oral presentations and abstracts. Before either party may submit any paper, oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any such paper is submitted abstract for publication or an oral presentation is madepublication, the publishing or presenting Party party proposing publication shall deliver a then-current complete copy of the paper or such materials for oral presentation to the other Party party at least *** 45 days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the date set for presentation. The other Party party shall review any such paper and give its comments to the publishing Party party within *** 30 days of the delivery of such paper to the other Partyparty. With respect to oral presentation materials and abstractsmaterials, the other Party party shall make reasonable efforts to expedite review of such materials materials, and shall return such items as soon as practicable to the publishing party with appropriate comments, if any, but in no event later than 30 days from the date of delivery to the other party. With respect to abstracts, the other party shall make reasonable efforts to expedite review of such abstracts, and shall return such items as soon as practicable to the publishing or presenting Party party with appropriate comments, if any, but in no event later than *** 10 days from the date of delivery to the other Partyparty. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the The publishing or presenting Party party shall comply with the other Partyparty’s request to delete references to such other Partythe non-publishing party’s Confidential Information in any such paper and will withhold publication of or other materials. Notwithstanding anything to the contrary in this Agreement, neither party shall have the right to publish in any such paper or form any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions Confidential Information of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to party without such investigators and institutionsother party’s prior written consent.

Publications. Each Following the exercise of a Lilly Option or a NextCure Option with respect to a given Collaboration Target, such Party recognizes that (the publication of papers regarding “Publishing Party”) and its Affiliates, licensees and sublicensees shall have the right to publish or present scientific or technical data, results of, and or other information regardingwith respect to any Lilly Compound or Lilly Product, activities under this Agreementor NextCure Compound or NextCure Product, including oral presentations and abstracts, may be beneficial to both Parties, respectively; provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each that neither Party shall have the right to, and shall not, publish or present any Joint Collaboration Target Confidential Information, Lilly Product Information, NextCure Product Information or Know-How of the other Party’s Product without the prior written consent of the other Party. Such prohibition shall not apply to filing or prosecution of Patent Rights by a Party in accordance with the terms and conditions of this Agreement. In the event that the Publishing Party or any of its Affiliates, licensees or sublicensees desires to make any such publication or presentation that would disclose Confidential Information of the other Party (the “Non-publishing Party”) about a Lilly Compound or Lilly Product, or NextCure Compound or NextCure Product, as applicable, or if a Publishing Party requests the Non-publishing Party’s consent to any publication, the Publishing Party shall afford the Non-publishing Party a period of thirty (30) days (or at least ten (10) days in the case of abstracts or oral presentations) to review and approve in advance any paper proposed manuscript not yet presented for publication and the Non-publishing Party may delay or prevent such publication as the Non-publishing Party in good faith believes necessary to protect its rights with respect to such Party’s Collaboration Targets, Collaboration Compounds or Products. Each Party shall be entitled to issue scientific publications with respect to the such Party’s Products or their testing in accordance with such Party’s internal guidelines without approval by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any and such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy be in control of the paper any publications or materials for oral presentation to the other Party at least *** days prior to *** Confidential material redacted and filed separately with the Commissionscientific presentations regarding such Party’s Products or their testing. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** days from the date of delivery to the other Party. If approval is not given or deemed given, either A Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other publish clinical trial information on such Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound online database in accordance with the Development Plan, to agree to terms substantially similar to those set forth its corporate policy. The scientific contributions of each Party will be noted as appropriate in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutionsall publications or presentations.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided that such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any the Licensed Compound in the Lead Indication Compounds or Licensed Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** days **] prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within [*** days **] of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** twenty-five (25) days from the date of delivery to the other Party. Failure to respond within such twenty-five (25) days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC Senior Officers or their delegates for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional [*** days **] in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators ****Text Omitted and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance Filed Separately with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Section with respect to such investigators and institutions.230.406

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreementpursuant to the Collaboration, including oral presentations and abstracts, may be beneficial to both Parties, ; provided that such publications are subject to reasonable controls to protect the Confidential InformationInformation of the Parties. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each a Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or *** Confidential Treatment Requested *** 45 abstract, that contains clinical data or pertains to results of clinical studies, any Research or other studies Pre-Clinical Development activities with respect to any Licensed Compound in the Lead Indication Program Antibodies, or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within [*** *] days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** *] days from the date of delivery to the other Party. If Failure to respond within the time periods set forth above shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will shall withhold publication of any such paper or any presentation of same for an additional [*** *] days in order to permit the Parties applicable Party to obtain Patent protection if either Party deems it necessaryin accordance with this Agreement. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication of results of the Program activities hereunder. Accordingly, neither Party shall publish, present, or otherwise disclose, and shall cause investigators and institutions with which it contracts for its Affiliates not to disclose, any material related to the conduct Program Antibodies or that includes any Program Specific Information without the prior written consent of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutionsother Party.

Publications. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studies, Clinical Trials or other studies with respect to any the Licensed Compound in the Lead Indication Product or that includes other data generated under this Agreement or which includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** forty-five (45) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** thirty (30) days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** thirty (30) days from the date of delivery to the other Party. Failure to respond within such thirty (30) days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC Dispute in accordance with Section 14.7 for resolution together with the reasons for withholding approvalresolution. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will shall withhold publication of any such paper or any presentation of same for an additional *** sixty (60) days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Trials for the Licensed Product with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this SectionSection 10.8, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 10.8 with respect to such investigators and institutions.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, or other studies with respect to any the Licensed Compound in the Lead Indication Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within [*** *] days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** *] days from the date of delivery to the other Party. Failure to respond within such [***] days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional [*** *] days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Studies with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plancontracts, to agree to terms substantially similar to those set forth in this SectionSection 9.5, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 9.5 with respect to such investigators and institutions.

Publications. Each Party recognizes that ZAI and UCB each acknowledge the publication other Party’s interest in publishing the results of papers regarding results of, its research in order to obtain recognition within the scientific community and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Informationadvance the state of scientific knowledge. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. AccordinglyHowever, each Party shall have also recognizes their mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information. Consequently, in the right event that a Party wishes to review and approve any paper proposed for make a publication by the other Party(including without limitation abstracts, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studiespapers, or other studies with respect verbal public presentations) related to any the discovery, Development, Manufacture or Commercialization of Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is madeCompounds and/or Licensed Products, the publishing or presenting Party it shall first deliver a then-current copy of the paper or materials for oral presentation to the other Party a copy of the proposed publication (or an outline in the case of a planned verbal presentation) at least [*** ] days prior to [*** Confidential material redacted ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the CommissionSecurities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. submitting the paper to a publisher EXECUTION VERSION submission for publication or making the presentation. The other reviewing Party shall review any such paper and give its comments have the rights (1) to request modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons and/or (2) to request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests modifications to the publication or presentation, the publishing Party within *** days shall edit such publication to prevent disclosure of trade secret or proprietary business information identified by the reviewing Party prior to submission of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing proposed publication or presenting Party with appropriate comments, if any, but in no event later than *** days from the date of delivery to the other Partypresentation. If approval is not given or deemed given, either the reviewing Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoingrequests a delay, the publishing or presenting Party shall comply with the other delay submission or presentation for a period of [*] days to enable patent applications protecting each Party’s request rights in such information to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound filed in accordance with Section 7.1. Upon expiration of such [*] days, the Development Planpublishing Party shall be free to proceed with the publication or presentation, subject to agree to terms substantially similar to those set forth compliance with any requests for modification as provided above. However, UCB agrees that it shall not (and shall ensure that its Affiliates and Third Party contractors do not) publish or otherwise publicly disclose in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutionsany publication or presentation of any data or information regarding [*] at any time [*].

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, or other studies Development activities with respect to any Licensed Compound in the Lead Indication New Collaboration Compounds or Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation; provided that the Parties may agree to a shorter period in exigent circumstances. The other Party shall review any such paper and give its comments to the publishing Party within [*** *] days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** *] days from the date of delivery to the other Party. Failure to respond within such [***] days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC JRDI or applicable JDC, as applicable for resolution together with the reasons for withholding approval. Notwithstanding If the foregoingJDC or JRDI, as applicable, does not resolve such dispute within [***] days, the publishing or presenting Party shall be entitled to publish such paper or make such presentation; provided that the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional [*** *] days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Studies with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plancontracts, to agree to terms substantially similar to those set forth in this SectionSection 15.5, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 15.5 with respect to such investigators and institutions.. Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 146

Publications. Each Party recognizes that the publication of scientific and medical papers regarding results of, of and other information regarding, activities under this Agreementregarding Products, including oral presentations and abstracts, may be beneficial to both Parties, Parties provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each a Party shall have the right to may review and approve comment on any paper material proposed for disclosure or publication by the other Party, including any such as by oral presentation presentation, manuscript or abstract, that contains clinical data relating to the Development, Manufacture or pertains to results of clinical studies, or other studies with respect to any Licensed Compound in the Lead Indication Commercialization Products or that includes Confidential Information of the other Party. Before any such paper material is submitted for publication or an disclosure (other than oral presentation is madematerials and abstracts, which are addressed below), the publishing or presenting Party proposing publication shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper material to a publisher or making the presentation. The initiating such other disclosure, and such other Party shall review any such paper material and give its comments to the publishing Party proposing publication within [*** *] days of the delivery of such paper material to the such other Party. With respect to oral presentation materials and abstracts, the Party proposing publication shall deliver a complete copy to the other Party at least [***] days prior to the anticipated date of the presentation, and such other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party proposing publication with appropriate comments, if any, but in no event later than [*** *] days from the date of delivery to the other non-publishing Party. If approval is not given or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the The publishing or presenting Party shall comply with the other Party’s request to delete references to such the other Party’s Confidential Information in any such paper material and will withhold shall delay any submission for publication or other public disclosure for a period of any such paper or any presentation of same for up to an additional [*** *] days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct purpose of clinical studies with respect preparing and filing appropriate patent applications. For clarity, this Section 0 is intended to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth the procedures for scientific and medical presentations and publications, and other public disclosures (e.g., press releases, investor presentations and the like) are addressed in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators 0 and institutionsSection 0.

Publications. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, or other studies Development activities with respect to any Licensed Compound in the Lead Indication New Collaboration Compounds or Products or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [*** *] days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation; provided that the Parties may agree to a shorter period in exigent circumstances. The other Party shall review any such paper and give its comments to the publishing Party within [*** *] days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*** *] days from the date of delivery to the other Party. Failure to respond within such [***] days shall be deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the JDC JRDI or applicable JDC, as applicable for resolution together with the reasons for withholding approval. Notwithstanding If the foregoingJDC or JRDI, as applicable, does not resolve such dispute within [***] days, the publishing or presenting Party shall be entitled to publish such paper or make such presentation; provided that the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional [*** *] days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Studies with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plancontracts, to agree to terms substantially similar to those set forth in this SectionSection 15.5, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 15.5 with respect to such investigators and institutions. 152 Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***].

Publications. Each Party recognizes that The Parties recognize the publication desirability of papers regarding publishing and publicly disclosing the results ofof clinical trials of pharmaceutical products. Accordingly, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent this Section 8.4 and coordination through designated representatives of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordinglyeach Party, each Party shall have be free to publicly disclose the right results of clinical trials that it sponsors involving Products, subject to [ * ] prior review and approve any paper proposed for publication by the other PartyParty for protection of its Confidential Information, including in a manner consistent with all applicable Laws. For purposes of this Section 8.4, [ * ] shall be deemed the sponsor of any oral presentation clinical trial conducted under the Development Plan. In addition, if a Party intends to publish articles in scientific or abstract, that contains clinical data medical journals or pertains to make public presentations of the results of such clinical studiestrials, or other studies with respect to any Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy of the paper or materials for oral presentation provide to the other Party through the designated representatives of each Party at least **its earliest opportunity with any such proposed abstracts, manuscripts or summaries of presentations. The Party receiving such abstract, manuscript or summary shall respond promptly through its designated representative, and in any event no later than [ * days ] after receipt of such proposed publication or presentation, with its comments, including any Confidential Information of such Party to be removed prior to publication or presentation. The Party making such publication or presentation agrees to remove [*** Confidential material redacted ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Commission. submitting the paper Securities and Exchange Commission pursuant to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** days Rule 406 of the delivery Securities Act of such paper to the other Party1933, as amended. With respect to oral presentation materials and abstracts, any Confidential Information identified by the other Party shall make reasonable efforts as to expedite review which it does not have a right of such materials and abstractsdisclosure hereunder, and will give due regard to comments furnished by such other Party and such comments shall return such items as soon as practicable not be unreasonably rejected. All publications involving Products made pursuant to this Section 8.4 shall be in accordance with any guidelines or strategies promulgated by the JDC and shall include appropriate acknowledgement consistent with standard scientific practice of any contributions of each Party to the publishing or presenting Party results being publicly disclosed (including acknowledgement to Adamas with appropriate comments, if any, but in no event later than *** days from the date of delivery respect to the other Party. If approval is not given or deemed givendesign of DM104, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalDM105, DM303, and DM304). Notwithstanding the foregoing, [ * ] publicly disclose the publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct results of clinical studies trials that [ * ] compliance with respect to any Licensed Compound in accordance with guidelines or strategies promulgated by the Development Plan, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutionsJDC.

Publications. Each Following the exercise of a Lilly Option or a NextCure Option with respect to a given Collaboration Target, such Party recognizes that (the publication of papers regarding “Publishing Party”) and its Affiliates, licensees and sublicensees shall have the right to publish or present scientific or technical data, results of, and or other information regardingwith respect to any Lilly Compound or Lilly Product, activities under this Agreementor NextCure Compound or NextCure Product, including oral presentations and abstracts, may be beneficial to both Parties, respectively; provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each that neither Party shall have the right to, and shall not, publish or present any Joint Collaboration Target Confidential Information, Lilly Product Information, NextCure Product Information or Know-How of the other Party’s Product without the prior written consent of the other Party. Such prohibition shall not apply to filing or prosecution of Patent Rights by a Party in accordance with the terms and conditions of this Agreement. In the event that the Publishing Party or any of its Affiliates, licensees or sublicensees desires to make any such publication or presentation that would disclose Confidential Information of the other Party (the “Non-publishing Party”) about a Lilly Compound or Lilly Product, or NextCure Compound or NextCure Product, as applicable, or if a Publishing Party requests the Non-publishing Party’s consent to any publication, the Publishing Party shall afford the Non-publishing Party a period of thirty (30) days (or at least ten (10) days in the case of abstracts or oral presentations) to review and approve in advance any paper proposed manuscript not yet presented for publication and the Non-publishing Party may delay or prevent such publication as the Non-publishing Party in good faith believes necessary to protect its rights with respect to such Party’s Collaboration Targets, Collaboration Compounds or Products. Each Party shall be entitled to issue scientific publications with respect to the such Party’s Products or their testing in accordance with such Party’s internal guidelines without approval by the other Party, including any oral presentation or abstract, that contains clinical data or pertains to results of clinical studies, or other studies with respect to any Licensed Compound in the Lead Indication or that includes Confidential Information of the other Party. Before any and such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current copy be in control of the paper any publications or materials for oral presentation to the other Party at least *** days prior to *** Confidential material redacted and filed separately with the Commissionscientific presentations regarding such Party’s Products or their testing. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** days from the date of delivery to the other Party. If approval is not given or deemed given, either A Party may refer the matter to the JDC for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other publish clinical trial information on such Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos shall cause investigators and institutions with which it contracts for the conduct of clinical studies with respect to any Licensed Compound online database in accordance with the Development Planits corporate policy. The scientific contributions of each Party will be noted as appropriate in all publications or presentations. [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, to agree to terms substantially similar to those set forth in this Section, which efforts shall satisfy Receptos’ obligations under this Section with respect to such investigators and institutionsAS AMENDED.

Publications. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, ; provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent patent application until such Patent application has been filed. Accordingly, each Party (a) Licensee shall have the right to review and approve approve, and (b) Licensor shall have the right to review and comment on, any paper proposed for publication by the other PartyParty or any of its Affiliates, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studiesClinical Studies, Phase IIIB Clinical Studies, Phase IV Clinical Studies, Post-Approval Commitments or other studies with respect to any the Licensed Compound Products for use in the Lead Indication Field or that includes other data generated under this Agreement or which includes Confidential Information of the other such first Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party (or its applicable Affiliate) shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** thirty (30) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments comments, if any, (and, in the case of Licensee as the reviewing Party, notify Licensor whether or not it is granting its approval) to the publishing Party within *** fifteen (15) days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** fifteen (15) days from the date of delivery to the other Party. If In the case of Licensee as the reviewing Party, failure to respond within such fifteen (15) days shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the The publishing or presenting Party (or its applicable Affiliate) shall consider the comments of the other Party in good faith and shall comply with the other Party’s 's request to delete references to such other Party’s 's Confidential Information in any such paper and will shall withhold publication of any such paper or any presentation of same for an additional *** sixty (60) days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use Commercially Reasonable Efforts to cause investigators and institutions participating in Clinical Studies, Phase IIIB Clinical Studies, Phase IV Clinical Studies or Post-Approval Commitments for the Licensed Products with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this SectionSection 11.7, which efforts shall satisfy Receptos’ such Party's obligations under this Section 11.7 with respect to such investigators and institutions.

Publications. The Joint Technical Committee shall discuss the overall strategy for, and coordinate, but have no right to approve or control publication and presentation of results of studies of Products or other data generated by CoTherix or its Affiliates or Sublicensees under this Agreement in support of Products worldwide, with the aim of obtaining Regulatory Approvals and optimizing Commercialization of the Products worldwide. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information that may be included in any invention disclosures or draft Patent patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data or which pertains to results of clinical studiesDevelopment, post approval studies or other studies with respect to any Licensed Compound in the Lead Indication Products or that includes other data generated under this Agreement or which includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** thirty (30) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing Party within *** fifteen (15) days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** fifteen (15) days from the date of delivery to the other Party. If Failure to respond within such fifteen (15) days shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the The publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and will withhold publication of any such paper or any presentation of same for an additional *** sixty (60) days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Development and post approval studies for the Products with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this SectionSection 8, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 8 with respect to such investigators and institutions. With respect to oral presentations, both Parties recognize the need to move quickly in special cases and under exigent circumstances. Therefore, in special circumstances such as late-breaking conference presentation opportunities the Parties shall cooperate so as to allow the Party who has the opportunity to make such presentation move quickly and not miss the opportunity. If either Party wishes for a draft publication or communication under this Section 8.5 to be translated into any language other than the original language, such Party shall be responsible to manage and pay for such translation.

Publications. Each Party recognizes that the publication of papers regarding results of, of and other information regarding, Technology regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties; provided, provided that such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data Clinical Data or pertains to results of clinical studies, Clinical Studies or includes other studies with respect to any Licensed Compound in the Lead Indication Technology generated under this Agreement or that includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a then-current complete copy of the paper or materials for oral presentation to the other Party at least *** thirty (30) days prior to *** Confidential material redacted and filed separately with the Commission. submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing or presenting Party within *** fifteen (15) days of after the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than *** fifteen (15) days from after the date of delivery to the other Party. If Failure to respond within such fifteen (15) days shall be deemed approval is not given to publish or deemed given, either Party may refer the matter to the JDC for resolution together with the reasons for withholding approvalpresent. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s written request to (a) delete references to such other Party’s Confidential Information in any such paper and will or presentation or (b) withhold publication of any such paper or any presentation of same for an additional *** sixty (60) days in order to permit the Parties to obtain Patent patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Receptos Each Party shall use commercially reasonable efforts to cause investigators and institutions participating in Clinical Studies for the Products with which it contracts for the conduct of clinical studies with respect to any Licensed Compound in accordance with the Development Plan, to agree to terms substantially similar to those set forth in this SectionSection 10.7, which efforts shall satisfy Receptos’ such Party’s obligations under this Section 10.7 with respect to such investigators and institutions.